266 related articles for article (PubMed ID: 15830401)
1. An open study of risperidone liquid in the acute phase of schizophrenia.
Yoshimura R; Nakamura J; Shinkai K; Goto M; Yamada Y; Kaji K; Kakihara S; Ueda N; Kohara K; Ninomiya H; Egami H; Maeda H
Hum Psychopharmacol; 2005 Jun; 20(4):243-8. PubMed ID: 15830401
[TBL] [Abstract][Full Text] [Related]
2. Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients.
Yoshimura R; Shinkai K; Ueda N; Nakamura J
Pharmacopsychiatry; 2007 Jan; 40(1):9-13. PubMed ID: 17327954
[TBL] [Abstract][Full Text] [Related]
3. [Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis].
Pajonk FG; Schreiner A; Peters S; Rettig K; Degner D; Rüther E
Fortschr Neurol Psychiatr; 2003 May; 71(5):249-54. PubMed ID: 12740756
[TBL] [Abstract][Full Text] [Related]
4. Risperidone in the treatment of psychotic depression.
Goto M; Yoshimura R; Kakihara S; Shinkai K; Yamada Y; Kaji K; Ueda N; Nakamura J
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):701-7. PubMed ID: 16580110
[TBL] [Abstract][Full Text] [Related]
5. Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study.
Hovens JE; Dries PJ; Melman CT; Wapenaar RJ; Loonen AJ
J Psychopharmacol; 2005 Jan; 19(1):51-7. PubMed ID: 15671129
[TBL] [Abstract][Full Text] [Related]
6. Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders.
Yoshimura R; Nakano Y; Hori H; Ikenouchi A; Ueda N; Nakamura J
Hum Psychopharmacol; 2006 Oct; 21(7):433-8. PubMed ID: 17029305
[TBL] [Abstract][Full Text] [Related]
7. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam.
Currier GW; Chou JC; Feifel D; Bossie CA; Turkoz I; Mahmoud RA; Gharabawi GM
J Clin Psychiatry; 2004 Mar; 65(3):386-94. PubMed ID: 15096079
[TBL] [Abstract][Full Text] [Related]
8. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
Baeza I; Castro-Fornieles J; Deulofeu R; de la Serna E; Goti J; Salvà J; Bernardo M
Psychiatry Res; 2009 Jul; 168(2):110-8. PubMed ID: 19501918
[TBL] [Abstract][Full Text] [Related]
9. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
Lasser RA; Bossie CA; Zhu Y; Gharabawi G; Eerdekens M; Davidson M
Int J Geriatr Psychiatry; 2004 Sep; 19(9):898-905. PubMed ID: 15352149
[TBL] [Abstract][Full Text] [Related]
11. Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.
Kakihara S; Yoshimura R; Shinkai K; Matsumoto C; Goto M; Kaji K; Yamada Y; Ueda N; Ohmori O; Nakamura J
Int Clin Psychopharmacol; 2005 Mar; 20(2):71-8. PubMed ID: 15729081
[TBL] [Abstract][Full Text] [Related]
12. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
[TBL] [Abstract][Full Text] [Related]
13. Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients.
Yoshimura R; Hori H; Sugita A; Ueda N; Kakihara S; Umene W; Nakano Y; Shinkai K; Mitoma M; Ohta M; Shinkai T; Nakamura J
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1072-7. PubMed ID: 17459549
[TBL] [Abstract][Full Text] [Related]
14. Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia.
Yoshimura R; Ueda N; Shinkai K; Nakamura J
Int Clin Psychopharmacol; 2003 Mar; 18(2):107-11. PubMed ID: 12598823
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of risperidone in Asian patients with schizophrenia in Singapore.
Chong SA; Yap HL; Low BL; Choo CH; Chan AO; Wong KE; Mahendran R; Chee KT
Singapore Med J; 1999 Jan; 40(1):41-3. PubMed ID: 10361485
[TBL] [Abstract][Full Text] [Related]
16. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T
Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763
[TBL] [Abstract][Full Text] [Related]
17. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation.
Chan HY; Lin AS; Chen KP; Cheng JS; Chen YY; Tsai CJ
J Clin Psychopharmacol; 2013 Dec; 33(6):747-52. PubMed ID: 24100785
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment with long-acting risperidone in Korean patients with schizophrenia.
Lee MS; Ko YH; Lee SH; Seo YJ; Kim SH; Joe SH; Han CS; Lee JH; Jung IK
Hum Psychopharmacol; 2006 Aug; 21(6):399-407. PubMed ID: 16915580
[TBL] [Abstract][Full Text] [Related]
19. Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets.
Normann C; Schmauss M; Bakri N; Gerwe M; Schreiner A
Pharmacopsychiatry; 2006 Nov; 39(6):209-12. PubMed ID: 17124642
[TBL] [Abstract][Full Text] [Related]
20. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
